Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

NCT01373151 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

418

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: BMS-945429 Placebo
BIOLOGICAL: BMS-945429
BIOLOGICAL: BMS-945429
BIOLOGICAL: BMS-945429
BIOLOGICAL: BMS-945429
DRUG: Methotrexate
DRUG: Methotrexate
DRUG: Methotrexate Placebo
DRUG: Methotrexate
DRUG: Adalimumab Placebo
DRUG: Adalimumab

Sponsor

CSL Behring